GlobeNewswire: Neothetics, Inc. Contains the last 10 of 50 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T01:24:19ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2018/01/05/1284399/0/en/Neothetics-Announces-Adjournment-of-Special-Stockholders-Meeting-to-Solicit-Additional-Votes-for-Merger-With-Evofem.html?f=22&fvtc=4&fvtv=24171Neothetics Announces Adjournment of Special Stockholders Meeting to Solicit Additional Votes for Merger With Evofem2018-01-05T22:15:00Z<![CDATA[SAN DIEGO, Jan. 05, 2018 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) today announced that the Special Meeting of Stockholders held earlier today was convened and adjourned without any business being conducted other than the adjournment. The meeting will reconvene on Wednesday, January 17, 2018 at 8:00 a.m., local time, at the same location, 4365 Executive Drive, Suite 1100, San Diego, CA 92121. The record date for stockholders entitled to vote at the special meeting will remain December 13, 2017.]]>https://www.globenewswire.com/news-release/2017/11/08/1177788/0/en/Neothetics-Provides-Business-Update-and-Reports-Third-Quarter-2017-Financial-Results.html?f=22&fvtc=4&fvtv=24171Neothetics Provides Business Update and Reports Third Quarter 2017 Financial Results2017-11-08T13:00:00Z<![CDATA[SAN DIEGO, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) provided a business update and reported financial results for the third quarter 2017.]]>https://www.globenewswire.com/news-release/2017/10/17/1148649/0/en/Neothetics-Inc-and-Evofem-Biosciences-Inc-Announce-Merger-Agreement-to-Create-Women-s-Health-Company.html?f=22&fvtc=4&fvtv=24171Neothetics, Inc. and Evofem Biosciences, Inc. Announce Merger Agreement to Create Women’s Health Company2017-10-17T12:00:00Z<![CDATA[SAN DIEGO, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) and Evofem Biosciences, Inc. today announced they have entered into a definitive agreement under which privately-held Evofem Biosciences will merge with a wholly-owned subsidiary of Neothetics in an all-stock transaction. The merger will position the combined company with an opportunity to become a leading women’s health company that develops and commercializes novel products. Upon closing of the transaction, Neothetics will be renamed Evofem Biosciences, Inc., and will be under the leadership of Evofem Biosciences’ Chief Executive Officer, Saundra Pelletier.]]>https://www.globenewswire.com/news-release/2017/08/10/1083201/0/en/Neothetics-Provides-Business-Update-and-Reports-Second-Quarter-2017-Financial-Results.html?f=22&fvtc=4&fvtv=24171Neothetics Provides Business Update and Reports Second Quarter 2017 Financial Results2017-08-10T12:00:00Z<![CDATA[SAN DIEGO, Aug. 10, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) provided a business update and reported financial results for the second quarter 2017.]]>https://www.globenewswire.com/news-release/2017/07/10/1042260/0/en/Neothetics-Announces-Review-of-Strategic-Alternatives.html?f=22&fvtc=4&fvtv=24171Neothetics Announces Review of Strategic Alternatives2017-07-10T21:45:00Z<![CDATA[SAN DIEGO, July 10, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) announced today that its Board of Directors has unanimously approved plans to initiate a process to explore and review a range of strategic alternatives focusing on seeking an acquisition, business combination or partnership that will allow for it to maximize shareholder value from its remaining assets and cash resources. Neothetics has engaged Oppenheimer and Co., Inc. to act as its exclusive financial advisor to the company and Board for this process. The Company also intends to streamline its operations in order to preserve its capital and cash resources, including implementing a reduction in workforce.]]>https://www.globenewswire.com/news-release/2017/06/26/1028964/0/en/Neothetics-Announces-Top-Line-Results-for-Phase-2-Proof-of-Concept-Study-of-LIPO-202-for-the-Reduction-of-Submental-Subcutaneous-Fat.html?f=22&fvtc=4&fvtv=24171Neothetics Announces Top-Line Results for Phase 2 Proof-of-Concept Study of LIPO-202 for the Reduction of Submental Subcutaneous Fat2017-06-26T12:00:00Z<![CDATA[LIPO-202 did not show efficacy in the reduction of submental fat LIPO-202 did not show efficacy in the reduction of submental fat]]>https://www.globenewswire.com/news-release/2017/05/11/982429/0/en/Neothetics-Provides-Business-Update-and-Reports-First-Quarter-2017-Financial-Results.html?f=22&fvtc=4&fvtv=24171Neothetics Provides Business Update and Reports First Quarter 2017 Financial Results2017-05-11T12:00:00Z<![CDATA[SAN DIEGO, May 11, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market today provided a business update and reported financial results for the first quarter 2017.]]>https://www.globenewswire.com/news-release/2017/05/04/978538/0/en/Neothetics-to-Provide-a-Business-Update-and-Release-First-Quarter-2017-Financial-Results-Thursday-May-11th-2017.html?f=22&fvtc=4&fvtv=24171Neothetics to Provide a Business Update and Release First Quarter 2017 Financial Results Thursday, May 11th, 20172017-05-04T12:00:00Z<![CDATA[SAN DIEGO, May 04, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, announced today that it will provide a business update and release its first quarter 2017 financial results before the market opens on Thursday, May 11, 2017.]]>https://www.globenewswire.com/news-release/2017/04/05/954672/0/en/Neothetics-Announces-Issuance-by-USPTO-of-Eighth-Patent-Directed-to-LIPO-202-Lead-Clinical-Asset.html?f=22&fvtc=4&fvtv=24171Neothetics Announces Issuance by USPTO of Eighth Patent Directed to LIPO-202 Lead Clinical Asset2017-04-05T12:00:00Z<![CDATA[SAN DIEGO, April 05, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market today announced the issuance of U.S. Patent Number 9,597,531 by the United States Patent and Trademark Office (USPTO).  This patent is directed to specific methods of using LIPO-202 and other agents for the reduction of fat accumulation. The ’531 patent is expected to expire no earlier than the fourth quarter of 2031, extending the coverage time of the company’s intellectual property portfolio. This is the eighth issued U.S. patent directed to Neothetics' lead product candidate LIPO-202, which is being evaluated for the reduction of submental fat.]]>https://www.globenewswire.com/news-release/2017/03/29/946334/0/en/Neothetics-to-Present-at-the-16th-Annual-Needham-Healthcare-Conference.html?f=22&fvtc=4&fvtv=24171Neothetics to Present at the 16th Annual Needham Healthcare Conference 2017-03-29T12:00:00Z<![CDATA[SAN DIEGO, March 29, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) today announced that Susan A. Knudson, Neothetics’ Chief Financial Officer, will present at the 16th Annual Needham Healthcare Conference on Wednesday, April 5th at 12:50 PM,  Eastern Time at the Westin Grand Central Hotel in New York City.]]>